替吉奥和卡培他滨分别联合奥沙利铂化疗对晚期胃癌疗效观察

目的:观察替吉奥和卡培他滨分别联合奥沙利铂治疗晚期胃癌近期疗效和不良反应。方法:48例晚期胃癌患者,随机分为2组,替吉奥组:替吉奥的给药剂量根据体表面积计算,≥ 1.25 m2,每次60 mg,每日2次,连续14 d,每3 周重复;卡培他滨组:卡培他滨的给药剂量根据体表面积计算,1 250 mg/m2,每日2次,连续14 d,每3周重复。2组分别加入奥沙利铂85 mg/m2,第1天,每3周重复。2个疗程后CT评价疗效。结果:替吉奥组有效率为62.5%,肿瘤控制率为79.2%,卡培他滨组有效率为58.3%,肿瘤控制率为83.3%。2组疗效和不良反应差异均无统计学意义(P>0.05)。替吉奥组最常见为3～4度血小板下降;卡培他滨组为3～4度白细胞下降。2组总体上不良反应较轻,耐受性好,没有与治疗相关的病死病例。结论:老年晚期胃癌患者可从替吉奥联合奥沙利铂或卡培他滨联合奥沙利铂的化疗中获益,不良反应可耐受。

Effect of the combination chemotherapy of gimeracil and oteracil porassium capsule or capecitabine with oxaliplatin on advanced gastric cancer

Objective: To observe the short-term effects and adverse reactions of the gimeracil and oteracil porassium capsule(S-1) or capecitabine combined with oxaliplatin in the treatment of advanced gastric cancer.Methods: Forty-eight patients with advanced gastric cancer were randomly divided into the S-1 group and capecitabine group.The S-1 group were treated with 60 mg of gimeracil and oteracil porassium capsule(the body surface area more than or equal 1.25 m2) twice a day for 14 days,3 weeks for a schedule.The capecitabine group were treated with 1 250 mg/m2 of capecitabine twice a day for 14 days,3 weeks for a schedule.The 85 mg/m2 of oxaliplatin were administered in two groups on the first day.The efficacy was evaluated by CT scan after 2 cycles.Results: The effective rates and tumor growth control rates in S-1 group and capecitabine group were 62.5% ＆ 79.2% and 58.3% ＆ 83.3%,respectively.The differences of effects and adverse reactions between two groups were not statistical significance(P>0.05).The blood platelet decreasing 3 to 4 grade in S-1 group and hemameba decreasing 3 to 4 grade in capecitabine group were found.The less side effects,good tolerance and no death case were observed.Conclusions: The gimeracil and oteracil porassium capsule or capecitabine combined with oxaliplatin in the treatment of advanced gastric cancer is good effect and less adverse reactions.